8-K: CG Oncology Announces Positive Data for Cretostimogene in Bladder Cancer Trial

CG Oncology reports promising results from its BOND-003 trial for cretostimogene in bladder cancer, showing durable complete responses and high recurrence-free survival rates.

Summary

• CG Oncology announced positive data from the BOND-003 Phase 3 clinical trial for cretostimogene grenadenorepvec at the American Urological Association Annual Meeting.
• Cohort C of the trial, involving patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), showed a 75.5% complete response (CR) rate at any time.
• 34 patients had confirmed CRs at 24 months, with 9 patients awaiting their 24-month assessment as of March 14, 2025.
• The 12and 24-month CR rates were 50.7% and 42.3% by K-M estimation, respectively.
• The median duration of response (DOR) is 28 months and is ongoing.
• 97.3% of patients were free from progression to muscle invasive disease at 24 months.
• Cohort P, involving patients with BCG-unresponsive Ta/T1 disease without CIS, showed an estimated 90.5% high-grade recurrence-free survival at 3 and 9 months in 24 treated patients.
• Cretostimogene was generally well-tolerated, with no Grade 3 or greater treatment-related adverse events (TRAEs) or deaths reported.

Sentiment

Score: 8

Explanation: The document presents positive clinical trial data, indicating potential for cretostimogene as a valuable treatment for bladder cancer. The high complete response rates and favorable safety profile contribute to a positive outlook.

Positives

• High complete response rates were observed in Cohort C, with 75.5% at any time and 42.3% at 24 months by K-M estimation.
• A high percentage of patients (97.3%) in Cohort C remained free from progression to muscle invasive disease at 24 months.
• Cohort P showed a 90.5% high-grade recurrence-free survival at 3 and 9 months.
• Cretostimogene was well-tolerated, with no Grade 3 or greater treatment-related adverse events or deaths reported.
• 97.3% of patients completed all expected treatments, demonstrating favorable patient adherence and compliance.

Risks

• Additional patient data may be inconsistent with the data reported.
• Earlier clinical trial results may not be predictive of future results.
• Unexpected adverse side effects or inadequate efficacy of cretostimogene may limit its development, regulatory approval, and/or commercialization.
• Potential delays in the commencement, enrollment, and completion of clinical trials could occur.
• Competitive developments in NMIBC treatments may adversely affect the commercial opportunity of cretostimogene.

Future Outlook

The company believes cretostimogene has the potential to be a backbone bladder-sparing therapeutic for patients with bladder cancer and offers distinct advantages over existing therapies for high-risk BCG-unresponsive NMIBC.

Management Comments

• 'We continue to see strong safety and efficacy, as well as best-in-disease durability and tolerability, with cretostimogene at the 24-month mark, in a high-risk, heavily pretreated NMIBC patient population,' said Gary D. Steinberg, M.D.
• Ambaw Bellete, President & Chief Operating Officer, CG Oncology, stated that the compelling efficacy, durability, freedom from progression to muscle-invasive disease, and tolerability of cretostimogene offer potential, distinct advantages over existing therapies.

Industry Context

The announcement highlights CG Oncology's progress in the competitive field of bladder cancer therapeutics, particularly in addressing the unmet need for patients with BCG-unresponsive NMIBC.

Comparison to Industry Standards

• The 42.3% 24-month complete response rate in the BOND-003 Cohort C study compares favorably to existing therapies for BCG-unresponsive NMIBC, such as Valrubicin, which has shown lower complete response rates.
• The 90.5% high-grade recurrence-free survival in Cohort P is a promising early signal, potentially positioning cretostimogene as a competitive option for patients with Ta/T1 disease without CIS.
• Companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo) have also been developing immunotherapies for bladder cancer, but cretostimogene's bladder-sparing approach offers a unique advantage.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients with bladder cancer may benefit from a potential new treatment option.
• Employees of CG Oncology may be motivated by the progress of cretostimogene.

Next Steps

• CG Oncology will host a conference call and webcast on April 28, 2025.
• The company plans to continue investigations of cretostimogene as a monotherapy and in future combinations.
• CG Oncology is working diligently to bring cretostimogene forward to patients.

Key Dates

Keywords

cretostimogene, bladder cancer, NMIBC, BOND-003, clinical trial, complete response, recurrence-free survival, CG Oncology